Listen on the go
Feedback
We’d love to hear your feedback on this activity. It helps us to continually improve our products.
CORRECT!
Faculty & Disclosures
Dr Dalia Rotstein
University of Toronto, ON, Canada
Dr Dalia Rotstein is a neurologist at St. Michael’s Hospital and an assistant professor at the University of Toronto, ON, Canada. Her research is focused on the epidemiology of multiple sclerosis and other demyelinating diseases in diverse populations, with the goal of promoting more inclusive care and equitable outcomes. read more
Dr Rotstein has a particular interest in the roles of sex, ethnicity, migration and Epstein-Barr virus infection in these conditions. She is the principal investigator for CANOPTICS, the first Canadian national prospective study to investigate adults with neuromyelitis optica spectrum disorders, myelin oligodendrocyte glycoprotein antibody-associated disease and other atypical demyelinating conditions.
Dr Dalia Rotstein discloses: Advisory board or panel fees from Alexion, Biogen, EMD Serono, Novartis, Roche and Sanofi. Grants/research support from Roche. Speaker’s bureau fees from Alexion, Biogen, EMD Serono, Novartis, Roche and Sanofi Aventis. Â
Dr Eoin Flanagan
Mayo Clinic, Rochester, MN, USA
Dr Eoin Flanagan is a professor of neurology and consultant in the departments of Neurology and Laboratory Medicine and Pathology at the Mayo Clinic, Rochester, MN, USA. He completed his neurology residency and was awarded fellowships in neuroimmunology and a masters in clinical and translational science at the Mayo Clinic, Rochester. read more
Dr Flanagan works in the Center for Multiple Sclerosis and Autoimmune Neurology clinics and the Neuroimmunology Laboratory at the Mayo Clinic. His clinical expertise and research are focused on myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders, transverse myelitis and other myelopathies, autoimmune encephalitis, paraneoplastic neurologic disorders and multiple sclerosis. He is a principal investigator on a National Institutes of Health research project grant studying MOGAD, and was a member of the International MOGAD panel that devised its diagnostic criteria.
Dr Eoin Flanagan discloses: Advisory board or panel fees from Alexion, Genentech, Horizon Therapeutics and UCB (All relationships terminated). Grants/research support from UCB. Â
Dr Jeffrey Bennett
University of Colorado, Aurora, CO, USA
Dr Jeffrey Bennett is the Gertrude Gilden professor for neurodegenerative disease research in the departments of Neurology and Ophthalmology at the University of Colorado (CU) School of Medicine, Aurora, CO, USA. He is also a faculty member of the programmes in immunology and neuroscience, and the Rocky Mountain MS Center at Anschutz Medical Campus, Aurora. read more
Dr Bennett directs basic, translational and clinical research programmes on neuromyelitis optica spectrum disorder (NMOSD), multiple sclerosis (MS), optic neuritis and myelin oligodendrocyte glycoprotein antibody-associated disease, and maintains active specialty practices in neuro-ophthalmology and neuroimmunology. He has received the Stephen Reingold Award from the National MS Society and the CU Experts Inventor of the Year Award.
Dr Bennett has been a leader in understanding the role of B cells in demyelinating disorders. Using single cell recombinant monoclonal antibody technology, his laboratory has probed the targets of the immune response in NMOSD and MS. His research in NMOSD has elucidated the pathogenicity of aquaporin-4 (AQP4) autoantibodies, identified B cell epitopes on AQP4 protein, and assisted in the development of novel antigen-specific therapies. He is widely published, and is a regular member of scientific review committees for the National Institutes of Health and the National MS Society.
Dr Jeffery Bennett discloses: Advisory board or panel fees from Clene Nanomedicine, Genentech and Roche. Consultancy fees from AbbVie (relationship terminated), Alexion Pharmaceuticals, Antigenomycs (relationship terminated), BeiGene, Chugai Pharmaceutical, Genentech, Genzyme (relationship terminated), Horizon Therapeutics, Imcyse, Mitsubishi Tanabe Pharma, Reistone Biopharma, Roche and TG Therapeutics. Grants/research support from Alexion, Mallinckrodt Pharmaceuticals and Novartis. Other financial or material support from Aquaporumab. Speaker’s bureau fees from Alexion. Â
